DOCSLIB.ORG

Drug-Induced Endocrinopathies and Diabetes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug-Induced Endocrinopathies and Diabetes 2 181 E Diamanti-Kandarakis and Drug-induced endocrinopathies 181:2 R73–R105 Review others and diabetes DIAGNOSIS OF ENDOCRINE DISEASE Drug-induced endocrinopathies and diabetes: a combo-endocrinology overview E Diamanti-Kandarakis1, L Duntas2, G A Kanakis3, E Kandaraki1, N Karavitaki4,5, E Kassi6, S Livadas7, G Mastorakos8, I Migdalis9, A D Miras10, S Nader11, O Papalou1, R Poladian12, V Popovic13, D Rachoń14, S Tigas15, C Tsigos16, T Tsilchorozidou17, T Tzotzas18, A Bargiota19 and M Pfeifer20 on behalf of COMBO ENDO TEAM: 2018 1Department of Endocrinology, Diabetes and Metabolism, Hygeia Hospital, 2Endocrine Clinic Evgenidion Hospital, University of Athens, 3Department of Endocrinology, Athens Naval & VA Hospital, Athens, Unit of Reproductive Endocrinology, Athens, Greece, 4Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, 5Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK, 6Department of Biological Chemistry, First Department of Internal Medicine, Laikon Hospital Medical School, NKUA, 7Endocrine Unit, Metropolitan Hospital, 8Endocrine Unit, 2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, ‘Aretaieion’ University Hospital, 9Second Medical Department and Diabetes Centre, NIMTS Hospital, Athens, Greece, 10Division of Endocrinology Diabetes and Metabolic Medicine, Imperial College London, London, UK, 11Department of Internal Medicine-Endocrine Division, McGovern Medical School, Houston, Texas, USA, 12Department of Endocrinology, MLH University Hospital, Beirut, Lebanon, 13School of Medicine, University of Belgrade, Belgrade, Serbia, 14Department of Clinical and Experimental Endocrinology, Medical Correspondence University of Gdańsk, Gdańsk, Poland, 15Department of Endocrinology, Ioannina University Hospital, Ioannina, Greece, should be addressed 16Harokopio University of Athens and HYGEIA Hospital, Athens, Greece, 17Private Practice, Endocrinologist, Serres, to E Diamanti-Kandarakis Greece, 18St. Luke’s Hospital, Panorama, Thessaloniki, Greece, 19Department of Internal Medicine – Endocrinology, Email University of Thessaly, Larissa, Greece, and 20Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia e.diamanti.kandarakis@ gmail.com Abstract In the currently overwhelming era of polypharmacy, the balance of the dynamic and delicate endocrine system can easily be disturbed by interfering pharmaceutical agents like medications. Drugs can cause endocrine abnormalities via different mechanisms, including direct alteration of hormone production, changes in the regulation of the feedback European Journal of Endocrinology axis, on hormonal transport, binding and signaling, as well as similar changes to counter-regulatory hormone systems. Furthermore, drugs can interfere with the hormonal assays, leading to erroneous laboratory results that disorientate clinicians from the right diagnosis. The purpose of this review is to cover a contemporary topic, the drug-induced endocrinopathies, which was presented in the monothematic annual Combo Endo Course 2018. This challenging part of endocrinology is constantly expanding particularly during the last decade, with the new oncological therapeutic agents, targeting novel molecular pathways in the process of malignancies. In this new context of drug-induced endocrine disease, clinicians should be aware that drugs can cause endocrine abnormalities via different mechanisms and mimic a variety of clinical scenarios. Therefore, it is extremely important for clinicians not only to promptly recognize drug- induced hormonal and metabolic abnormalities, but also to address the therapeutic issues for timely intervention. European Journal of Endocrinology (2019) 181, R73–R105 Invited Author’s profile Evanthia Diamanti-Kandarakis is a Professor of Internal Medicine and Endocrinology and Chairman of the Department of Endocrinology and Diabetes HYGEIA Hospital in Athens, Greece. Her research interests have focused for the last 25 years on clinical, molecular and environmental aspects of metabolic and hormonal abnormalities in obesity diabetes and polycystic ovarian syndrome. https://eje.bioscientifica.com © 2019 European Society of Endocrinology Published by Bioscientifica Ltd. https://doi.org/10.1530/EJE-19-0154 Printed in Great Britain Downloaded from Bioscientifica.com at 09/27/2021 10:34:28PM via free access -19-0154 E Diamanti-Kandarakis and Drug-induced endocrinopathies others and diabetes https://eje.bioscientifica.com checkpoint (ICP)inhibitors have ledtoagreatreliefand The immunetherapiesinadvanced cancerswithimmune Drug-induced hypopituitarism Drug-induced pituitary dysfunction along withtheirbroadspectrumofendocrinesideeffects. drug categoriesthatwillbeanalyzedinthefollowingtext, appropriate decisionforthetherapeuticintervention. role ofmeticulousmedicalhistory inordertomakethe differential diagnosis,emphasizingtheindisputable diabetes, inordertomakeitanintegralpartofclinicians’ promptly recognizingdrug-inducedendocrinopathiesand vigilance in clinicians’ raise the aim to we Conclusively, abnormalities leadingtoendocrinopathiesanddiabetes. recognize thedrug-inducedhormonalandmetabolic the underlyingpathophysiologicalmechanismsto to gobeyondalistofadverseeffectsandviaunderstanding made effort is In thisapproach,an metabolic disorders. and encountered inclinicalpractice,whichinduceendocrine overview ofacontemporary spectrumofdrugs, that disorientatecliniciansfromtherightdiagnosis( hormonal assays,leadingtoerroneouslaboratory results systems ( well assimilarchangestocounter-regulatory hormone axis andonhormonaltransport,binding,signaling,as production, changesintheregulationoffeedback mechanisms, includingdirectalterationofhormone broadening challengetoourclinicalpractice. a double-edgedswordforourpatients’wellbeingand estimated atUS$30 1000 peopleeachyear( per responsible forfourhospitalizations reactions are drug States, adverse the United systems. In healthcare morbidity hasbeenhighlightedasamajorburdenof more drugssystematically( of olderadultsintheUnitedStatesaretakingfiveor abnormalities. medications whichcanleadtoendocrineandmetabolic system canbedisturbedbymultiplefactorslikedrugsand polypharmacy ( system andorgan.Inthecurrentlyoverwhelming eraof multiple mechanismsmaintainshomeostasisinevery The endocrinesystemwithitspreciseinteractionsthrough Introduction Review The purposeofthisreviewistodelineatea‘combo’ Drugs cancauseendocrineabnormalitiesviadifferent It isestimatedthat10%ofthepopulationand30% Table 1 6 ). Furthermore, drugs can interfere with the ). Furthermore,drugscaninterferewiththe summarizessomethemostcommonlyused 1 ), thebalanceofdynamicendocrine billion ( 4 ), withassociatedannualcosts 2 , 5 ). Therefore,drugscanbe 3 ). Asaresult,drug-related European Journal of Endocrinology 7 ). Table 1 Commonly used drug categories with broad endocrine side effects. Immune Anabolic Androgen checkpoint Antiepileptic androgenic Oral Aromatase deprivation Cytotoxic inhibitors Opioids Psychotropics drugs Glucocorticoids steroids contraceptives inhibitors therapy Antihypertensives agents Drug-induced pituitary + + + dysfunction Drug-induced SIADH + + + + + Drug-induced + + + + (verapamil, methyldopa) hyperprolactinemia Drug-induced thyroid + + + + (beta-blockers) + Downloaded fromBioscientifica.com at09/27/202110:34:28PM abnormalities Drug-induced calcium and + + + + + (thiazides) + vitamin D deregulation Drug-induced osteoporosis + + + + + + + (loop diuretics) + Drug-induced obesity + + + + + Drug-induced diabetes + + + + + + + (calcium channel blockers, + diazoxide, clonidine) Drug-induced dyslipidemia + + + + + + + 181 Drug-induced adrenal + + + + :2 dysfunction Drug-induced pheo crisis + + + + (beta-blockers) Drug-induced amenorrhea + + + + + + + + (spironolactone) + Drug-induced + + + hyperandrogenemia Drug-induced PCOS + + + R74 Drug-induced male infertility + + + + + + + + (beta-blockers, + via freeaccess and sperm abnormalities spironolactone) Review E Diamanti-Kandarakis and Drug-induced endocrinopathies 181:2 R75 others and diabetes much greater hope in patients and physicians (8). In the antigen on an antigen-presenting cell (APC). The second past 15 years, ICP inhibitors have emerged as a promising signal involves the binding of a T-cell CD28 receptor to and expanding class of anticancer agents, and their use the B7 ligand on the APC. CTLA4 receptors on the surface has resulted in the alteration of the natural history of of T cells are able to compete with CD28 for binding to certain types of cancer (9, 10). the B7 ligands, thus inhibiting T-cell-mediated immune Along with the promising results in the patients responses. ICP inhibitors are monoclonal antibodies that who respond to these therapies, the modulation of block the proteins from binding to the tumor cells and immune response can result in a number of immune- APCs, thereby taking off the brake and allowing the T-cell related adverse events (IRAEs) affecting almost all organ to recognize and attack the tumor cells (Fig. 1). systems. Typically, IRAEs affect the skin, gastrointestinal The use of CTLA4 and PD1/PDL1 antibodies allows system, the lung, musculoskeletal, renal and nervous the activation of T lymphocytes who set sight on the system. Interestingly, endocrine system IRAEs are also endocrine glands causing thyroid dysfunction in 15%, commonly involved. The most common of them include hypophysitis in 9–11%, adrenalitis in 1% and diabetes hypophysitis and thyroid
Load more

Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • Spectrum of Benign Breast Diseases in Females- a 10 Years Study
    Original Article Spectrum of Benign Breast Diseases in Females- a 10 years study Ahmed S1, Awal A2 Abstract their life time would have had the sign or symptom of benign breast disease2. Both the physical and specially the The study was conducted to determine the frequency of psychological sufferings of those females should not be various benign breast diseases in female patients, to underestimated and must be taken care of. In fact some analyze the percentage of incidence of benign breast benign breast lesions can be a predisposing risk factor for diseases, the age distribution and their different mode of developing malignancy in later part of life2,3. So it is presentation. This is a prospective cohort study of all female patients visiting a female surgeon with benign essential to recognize and study these lesions in detail to breast problems. The study was conducted at Chittagong identify the high risk group of patients and providing regular Metropolitn Hospital and CSCR hospital in Chittagong surveillance can lead to early detection and management. As over a period of 10 years starting from July 2007 to June the study includes a great number of patients, this may 2017. All female patients visiting with breast problems reflect the spectrum of breast diseases among females in were included in the study. Patients with obvious clinical Bangladesh. features of malignancy or those who on work up were Aims and Objectives diagnosed as carcinoma were excluded from the study. The findings were tabulated in excel sheet and analyzed The objective of the study was to determine the frequency of for the frequency of each lesion, their distribution in various breast diseases in female patients and to analyze the various age group.
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Lupus Mastitis
    Published online: 2021-07-31 SPECIAL SYMPOSIUM - BREAST Lupus mastitis - peculiar radiological and pathological features Abdul Majid Wani, Waleed Mohd Hussain, Mohamed I Fatani, Bothaina Abdul Shakour Department of Radiology, Hera General Hospital, Makkah-10513, Saudi Arabia Correspondence: Dr Abdul Majid Wani, Hera General Hospital, Makkah-105 13, Saudi Arabia, E-mail: [email protected] Abstract Lupus mastitis is a form of lupus profundus that is seen in patients with systemic lupus erythematosus. It usually presents as a swelling (or swellings) in the breasts, with or without pain. The condition is recurrent and progresses along with the underlying disease, with fat necrosis, calcification, fibrosis, scarring, and breast atrophy. Lupus mastitis is often confused with malignancy and lymphoma and, in our part of the world, with tuberculosis. Confusion is especially likely when it occurs in an unusual clinical setting. In this article, we present a case that presented with unique radiological, pathological, and clinical features. Awareness of the various manifestations of lupus mastitis is essential if unnecessary interventions such as biopsies and surgeries, and their consequences, are to be avoided. Key words: Biopsy; lupus mastitis; lupus profundus; mammography; fine needle aspiration cytology; systemic lupus erythematosus Introduction hospital) was present and the patient reported that she had received antituberculous medication for 1 month at that Systemic lupus erythematosus (SLE) is a multisystem, time. Two 1 × 1.5 cm lymph nodes were present in the left autoimmune disorder. Involvement of the subcutaneous axillary region. The left breast revealed multiple lumps, the fat was termed as lupus profundus by Iregang.[1] Lupus biggest being 4 × 3 cm in size.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Medications to Treat Opioid Use Disorder Research Report
    Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States.
    [Show full text]
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Off Enders
    How to select pharmacologic treatments to manage recidivism risk in sex off enders Consider patient factors when choosing off -label hormonal and nonhormonal agents ® Dowden Healthex offenders Media traditionally are managed by the criminal justice system, but psychiatrists are fre- Squently called on to assess and treat these indi- CopyrightFor personalviduals. use Part only of the reason is the overlap of paraphilias (disorders of sexual preference) and sexual offending. Many sexual offenders do not meet DSM criteria for paraphilias,1 however, and individuals with paraphil- ias do not necessarily commit offenses or come into contact with the legal system. As clinicians, we may need to assess and treat a wide range of sexual issues, from persons with paraphilias who are self-referred and have no legal involvement, to recurrent sexual offenders who are at a high risk of repeat offending. Successfully managing sex offenders includes psychological and pharmacologic interven- 2009 © CORBIS / TIM PANNELL 2009 © CORBIS / tions and possibly incarceration and post-incarceration Bradley D. Booth, MD surveillance. This article focuses on pharmacologic in- Assistant professor terventions for male sexual offenders. Department of psychiatry Director of education Integrated Forensics Program University of Ottawa Reducing sexual drive Ottawa, ON, Canada Sex offending likely is the result of a complex inter- play of environment and psychological and biologic factors. The biology of sexual function provides nu- merous targets for pharmacologic intervention, in- cluding:2 • endocrine factors, such as testosterone • neurotransmitters, such as serotonin. The use of pharmacologic treatments for sex of- fenders is off-label, and evidence is limited. In general, Current Psychiatry 60 October 2009 pharmacologic treatments are geared toward reducing For mass reproduction, content licensing and permissions contact Dowden Health Media.
    [Show full text]
  • Pharmacological Interventions with Adult Male Sexual Offendersi
    Pharmacological Interventions with Adult Male Sexual Offendersi Adopted by the ATSA Executive Board of Directors on August 30, 2012 Introduction The treatment of sexual offending behaviors is complex and involves multiple etiologies, individualized risk reduction and risk management needs, and heterogeneous biopsychosocial, interpersonal, and legal factors. Clinicians and researchers have attempted to identify approaches which promise the greatest success in addressing these behaviors. Findings from a meta-analysis examining the effectiveness of various treatment interventions for adult sex offenders indicated that, when used in combination with other treatment approaches, biological interventions like testosterone-lowering hormonal treatments may be linked to greater reductions in recidivism for some offenders than the use of psychosocial treatments alone (Losel and Schmucker, 2005). Other data, described below, suggest that non- hormonal psychotropic medications can also be effective supplements to standard therapeutic interventions for sex offenders as well. This document is designed to provide an overview of key issues pertaining to the use of hormonal and non- hormonal agents to reduce or inhibit sexual arousal and recidivism in some sexual offenders.ii Mechanism-of- action, anticipated results of medication administration, side effects, ethical considerations, and empirical evidence regarding efficacy of pharmacological interventions will be highlighted. It should be noted that pharmacological interventions are not typically used for all sexual offenders, but are often applied to those with paraphilias or offense-specific patterns of sexual arousal which could be altered through the use of such interventions. Further, such interventions should be integrated into a comprehensive treatment program that addresses other static and dynamic risk factors that contribute to sexual offending.
    [Show full text]
  • Attachment: Extract from Clinical Evaluation Bosentan
    AusPAR Attachment 1 Extract from the Clinical Evaluation Report for Bosentan Proprietary Product Name: Tracleer Sponsor: Actelion Pharmaceuticals Australia Pty Ltd First round report: 25 October 2016 Second round report: 3 February 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About the Extract from the Clinical Evaluation Report · This document provides a more detailed evaluation of the clinical findings, extracted from the Clinical Evaluation Report (CER) prepared by the TGA. This extract does not include sections from the CER regarding product documentation or post market activities. · The words [Information redacted], where they appear in this document, indicate that confidential information has been deleted. · For the most recent Product Information (PI), please refer to the TGA website <https://www.tga.gov.au/product-information-pi>.
    [Show full text]
  • LOKELMA Is Sodium Zirconium Cyclosilicate, a Potassium Binder
    HIGHLIGHTS OF PRESCRIBING INFORMATION • For oral suspension: 10 g per packet (3) These highlights do not include all the information needed to use LOKELMA™ safely and effectively. See full prescribing information for ------------------------------ CONTRAINDICATIONS ----------------------------­ LOKELMA™. None. (4) ----------------------- WARNINGS AND PRECAUTIONS ---------------------­ LOKELMA™ (sodium zirconium cyclosilicate) for oral suspension • Gastrointestinal Adverse Events in Patients with Motility Disorders. Initial U.S. Approval: [2018] (5.1) --------------------------- INDICATIONS AND USAGE -------------------------­ • Edema. (5.2) LOKELMA is a potassium binder indicated for the treatment of hyperkalemia in adults. (1) ------------------------------ ADVERSE REACTIONS ----------------------------­ Most common adverse reactions with LOKELMA: mild to moderate edema. Limitation of Use (6.1) LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. ---------------------- DOSAGE AND ADMINISTRATION ---------------------­ • Recommended starting dose is 10 g administered three times a day for ------------------------------ DRUG INTERACTIONS ----------------------------­ up to 48 hours. (2.1) In general, other oral medications should be administered at least 2 hours • For maintenance treatment, recommended dose is 10 g once daily. (2.1) before
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]